DermTech Inc

DermTech, Inc. engages in the development and sale of products for the diagnosis and treatment of skin diseases. It markets and develops products that facilitate diagnosis and management of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. Its products and services include melanoma test, smart sticker, and telemedicine option for melanoma test. The company was founded in 1995 and is headquartered in La Jolla, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

DermTech reports 27% sequential revenue growth, focuses on reimbursed tests

DermTech is focused on expanding coverage for the DermTech Melanoma Test and stabilizing ASP. The company is frustrated with national payers' interpretation of their test data and is prioritizing generating reimbursed tests to increase revenue. Despite challenges, they have sufficient cash resources and are making progress with commercial payers and cost-saving measures.

DermTech prioritizes reimbursed tests, faces volume challenges, and seeks growth

DermTech's Q2 2023 earnings call showcased a strategic shift towards prioritizing reimbursed tests, resulting in declining sample volume and test revenue. Despite challenges in volume growth, the company's progress with insurance providers and leadership's excitement about the DMT highlight strengths. Opportunities lie in increasing ASP, test revenue, and covered lives, as well as reorienting efforts around the DMT for revenue growth.

DermTech reports revenue growth and legislative opportunities in Q3 2023

DermTech's Q3 2023 performance reflects revenue growth and progress in prioritizing reimbursed tests. The company faces challenges in navigating potential impacts of biomarker bills and ensuring effective communication with payers. However, opportunities for growth and expanded coverage present promising prospects for the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DermTech, Inc. engages in the development and sale of products for the diagnosis and treatment of skin diseases. It markets and develops products that facilitate diagnosis and management of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. Its products and services include melanoma test, smart sticker, and telemedicine option for melanoma test. The company was founded in 1995 and is headquartered in San Diego, CA.

DermTech's PLA stickers can help to diagnose melanoma despite being lower cost, more accurate, and less invasive compared to standard surgical biopsies.With 4-4.5mil surgical biopsies per year and an average reimbursement of $760, the TAM is more than $3bil.

DermTech: Stickers To Diagnose Cancer

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the topline results from its TRUST Study of the company's non-invasive melanoma rule-out test, the Pigmented Lesion Assay (the “PLA”). The TRUST study is a long-term follow-up study of pigmented skin lesions that tested negative for melanoma with the PLA. It was designed to assess long-term outcomes of PLA negative tes

DermTech Announces Topline Results of its TRUST Study: Results Confirm the High Negative Predictive Value of the PLA at 99% and Find No Significant Adverse Outcomes After Long-Term Follow-Up of PLA Negative Tests

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its inclusion in two CME sessions, at the Fall Clinical Dermatology Virtual Grand Rounds (the “FCVGR”) and the 23rd Annual Mount Sinai Winter Symposium “Advances in Medical and Surgical Dermatology” (the “Mount Sinai Symposium”). The FCVGR presentation was led by Laura K Ferris, MD, PhD of the University of Pittsburgh

DermTech's Melanoma Test Included in Two Continuing Medical Education (“CME”) Sessions at 2020 Fall Clinical Virtual Grand Rounds and Mount Sinai Winter Symposium

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it has entered into an agreement, effective February 1, 2021, with Blue Shield of California for reimbursement coverage for all of its products. Blue Shield of California has approximately 3.7 million covered lives in California through its Commercial PPO/EPO, Medicare Advantage PPO, Commercial HMO and Medicare Advanta

DermTech Enters Into Agreement With Blue Shield of California

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the presentation of a precision medicine focused session at the fourth annual Dermatology Drug Development Summit. Held virtually this year, the Dermatology Drug Development Summit is the only industry-focused meeting dedicated to innovating, accelerating, and sharing pharmaceutical best practice on the development and

DermTech Presents Updates in Precision Medicine at 2020 Dermatology Drug Development Summit

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it has entered into an agreement, effective November 3, 2020, with Blue Cross Blue Shield of Illinois for its Commercial PPO and Medicare Advantage membership. DermTech's PLA is the first non-invasive gene expression test for the early detection of melanoma. The PLA has a 99% negative predictive value (“NPV”), meaning

DermTech Enters Agreement with Blue Cross Blue Shield of Illinois

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech Presents New Clinical Research Abstract at the 2020 Fall Clinical Dermatology Conference

DermTech Presents New Clinical Research Abstract at the 2020 Fall Clinical Dermatology Conference

Innovative Industrial Properties

Trupanion

Great things appear to be in store for these rising stars.

Buying These 3 Stocks Could Make You Rich Over the Next Decade

DermTech, Inc. (DMTK) CEO John Dobak on Q3 Results - Earnings Call Transcript

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported unaudited financial results as of and for the quarter ended September 30, 2020. Third Quarter Highlights Assay revenues of $1.2 million for the third quarter of 2020, a 220% increase compared to the third quarter of 2019 and a 90% sequential increase over the second quarter of 2020. Billable sample volume of approximate

DermTech Reports Third Quarter 2020 Financial Results

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that Company management will participate in the following upcoming investor conferences: Stifel 2020 Virtual Healthcare Conference Presenting on Wednesday, November 18, 2020 at 1:20 p.m. Eastern time Canaccord Genuity Virtual MedTech & Diagnostics Forum Presenting on Thursday, November 19, 2020 at

DermTech to Participate in Upcoming Investor Conferences

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech to Announce Third Quarter 2020 Financial Results on November 10, 2020

DermTech to Announce Third Quarter 2020 Financial Results on November 10, 2020

Semler Scientific

Discover how these three companies could change the face of healthcare.

3 Healthcare Stocks to Watch

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech Announces Appointment of Chief Scientific Officer

DermTech Announces Appointment of Chief Scientific Officer

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc.

DermTech, Inc. Reports Second Quarter 2020 Financial Results and Provides Corporate Update

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that as part of the annual reconstitution of the Russell stock indexes, DermTech has been selected to be added to the Russell 2000® Index effective June 26, 2020. “We are pleased to have earned our inclusion in the Russell 2000® Index, one of the most widely cited performance benchmarks for small-cap companies,” said J

DermTech Announces Inclusion in the Russell 2000 Index

Blink Charging

Cocrystal Pharma

Tetraphase Pharmaceuticals

This week has been a successful one for markets, with the S&P 500 entering positive territory on the year. If you’re looking to hedge the rally, our deep learning algorithms have identified several top shorts for your portfolio.

Top Companies To Short As Stock Market Continues To Rally

Shares of precision dermatology company DermTech Inc (NASDAQ: DMTK) are rallying Thursday after receiving Medicare coverage for its diagnostic test to rule out skin cancer.

News for DermTech Inc Stock (DMTK)